Phenylpiracetam and Semax Interaction: Monitor | Peptide Database

Join others researching Exemestane — share findings, ask questions, and learn from real experiences Exemestane is a steroidal, irreversible aromatase inhibitor (often called a suicide inhibitor) that permanently inactivates the aromatase enzyme (CYP19A1), preventing conversion of androgens into estrogens. It is FDA-approved under the brand name Aromasin for the treatment of hormone receptor-positive breast cancer in postmenopausal women, particularly after prior tamoxifen therapy. In bodybuilding and hormone optimization, exemestane is valued for two properties that distinguish it from nonsteroidal AIs like anastrozole: its irreversible binding mechanism means there is no estrogen rebound when the drug is discontinued, and its steroidal structure confers mild androgenic activity that may partially offset some of the joint and mood side effects associated with estrogen suppression. Because exemestane permanently destroys aromatase molecules rather than temporarily blocking them, estrogen levels recover only as the body synthesizes new enzyme -- a process that takes several days. A common rule of thumb from community dosing guidelines: weekly testosterone dose (mg) divided by 20 equals mg of exemestane per week. For example, 500 mg of testosterone per week corresponds to approximately 25 mg of exemestane per week. This is a rough starting point only -- individual aromatization rates vary widely, and dosing should always be guided by bloodwork. Exemestane functions as a mechanism-based (suicide) inhibitor of aromatase (cytochrome P450 19A1). Due to its steroidal structure, exemestane is recognized by aromatase as a substrate analogue and enters the enzyme's active site. Once bound, aromatase processes exemestane, generating an intermediate that covalently and irreversibly binds to the enzyme, permanently inactivating it. This is fundamentally different from competitive, reversible inhibitors like anastrozole and letrozole, which dissociate from the enzyme over time. The irreversible nature of exemestane's inhibition means that aromatase activity can only recover through de novo synthesis of new enzyme protein, which typically takes 2-3 days. At the standard 25mg daily dose, exemestane reduces circulating estradiol by approximately 85-95% in postmenopausal women. In men using exogenous testosterone, the degree of suppression varies with dose and individual aromatization rates. A clinically relevant advantage of this irreversible mechanism is the absence of estrogen rebound: when exemestane is discontinued, estrogen levels rise gradually as new aromatase is synthesized, rather than surging back as accumulated substrate is rapidly converted (a phenomenon that can occur when reversible AIs like anastrozole are abruptly stopped). Additionally, exemestane and its primary metabolite 17-hydroexemestane possess mild androgenic activity, binding weakly to the androgen receptor. This androgenic property may help preserve bone mineral density and joint comfort relative to nonsteroidal AIs, though the clinical significance in men on exogenous androgens is modest.

YK-11's dual mechanism of AR agonism and myostatin inhibition theoretically positions it as a potent anabolic compound for increasing lean muscle mass. Cell culture data supports increased anabolic signaling and follistatin expression. However, there is no in vivo or clinical evidence confirming these effects in animals or humans. All efficacy reports are anecdotal. Users anecdotally report significant strength gains during YK-11 cycles, consistent with the compound's theoretical mechanism of action. The combination of AR-mediated protein synthesis and myostatin inhibition could theoretically support enhanced force production. No controlled studies exist to verify these claims. The most distinctive proposed benefit of YK-11 is its ability to upregulate follistatin and thereby inhibit myostatin-mediated limitations on muscle growth. In cell culture, YK-11 induced greater follistatin expression than DHT. If this translates to in vivo activity, it could allow muscle growth beyond normal physiological limits. This remains entirely unproven outside of cell-based assays. Follistatin has been shown in other research contexts to positively influence bone mineral density and bone formation. If YK-11's follistatin-inducing effects translate in vivo, there could be secondary benefits for bone density. This is entirely speculative and unsupported by any direct YK-11 bone data.